Carlyle is to acquire a significant minority stake in CureApp, Inc, a Japanese medical technology (medtech) company and prescription digital therapeutics provider, for JPY7 billion as part of CureApp’s Series G funding.
Carlyle’s investment brings the total amount of capital raised by CureApp to approximately JPY13.4 billion. Carlyle will have one board seat as part of the transaction.
Carlyle has invested more than JYP394.4 billion of equity in deals in Japan to-date; and has well-established experience investing in the healthcare sector in the country, with investments in Sunsho Pharmaceutical Co, Solasto Corporation, Qualicaps Co, and Colin Medical Technology. Globally, Carlyle has invested more than $19.5 billion of equity in over 75 deals in the healthcare sector as of 30 June, 2022.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.